SPOTLIGHT -
Experts on polycythemia vera provide a comprehensive overview of the objectives and study design of the MAJIC-PV clinical trial, highlighting key endpoints.
New Study Confirms Economic Burden of Chronic Lymphocytic Leukemia on Medicare Beneficiaries
The study found that the average annual costs for individuals with Chronic lymphocytic leukemia (CLL) were significantly higher compared to a matched non-CLL cohort.
Read More
Daratumumab Therapy Effective for Newly Diagnosed High-Risk Multiple Myeloma
Darzalex (daratumumab) is a monoclonal antibody drug currently approved for both refractory and new multiple myeloma. It’s available in intravenous and subcutaneous formulations.
FDA Advisory Committee Supports New Surrogate Endpoint To Assess Multiple Myeloma Treatments
This decision may lead to faster approval of new treatments for multiple myeloma.
Equity in Healthcare: Addressing Disparities in CAR T-Cell Therapy Access for Minority Patients with Large B-Cell Lymphomas
A recent study published in NEJM Evidence suggests that minority patients may not have equal access to CAR T-cell therapies, despite the potential life-saving benefits they offer.
FDA Approves Carvykti for Earlier Treatment in Multiple Myeloma
The decision comes after the FDA Oncologic Drugs Advisory Committee provided a unanimous vote recommending approval. Carvykti is now available to treat patients after just one prior line of therapy.
FDA Approves Abecma, a CAR-T Treatment, for Earlier Treatment of Multiple Myeloma
The chimeric antigen receptor T-cell (CART-T) therapy is now approved to treat patients with multiple myeloma after two prior lines of therapy.